Our Science
Stemcardia founders have dedicated decades of research to the challenge of repairing damaged heart tissue. Breakthroughs in the manufacture, use, and potency of cardiac cells enable new opportunities to restore function to the heart.
To ensure that our products reach their potential to treat tens of millions of patients in the US and globally, we manufacture our products with off-the-shelf technologies suited to commercial development and outpatient administration.
Our Technology
We use bioreactors to grow clinically relevant quantities of cardiac cells.
Our cardiac cells re-muscularize and rescue heart function following injury.
Publications
(2023) Silvia Marchiano et al. Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy. Cell Stem Cell. 30(4):396-414.
(2022) Elaheh Karbassi et al. Flexing Their Muscles: Maturation of Stem Cell-Derived Cardiomyocytes on Elastomeric Substrates to Enhance Cardiac Repair. Circulation. 145(18):1427-1430.
(2021) Kenta Nakamura et al. Pharmacologic therapy for engraftment arrhythmia induced by transplantation of human cardiomyocytes. Stem Cell Reports. 16(10):2473-2487.
(2020) Elaheh Karbassi et al. Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine. Nat Rev Cardiol. 17(6):341-359.
(2020) Charles E Murry, W Robb MacLellan. Stem cells and the heart—the road ahead. Science. 367(6480):854-855.
(2018) Alessandro Bertero, Charles E Murry. Hallmarks of cardiac regeneration. Nat Rev Cardiol. 15(10):579-580.
(2018) Yen-Wen Liu et al. Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates. Nat Biotechnol. 36(7):597-605.
(2017) Shin Kadota et al. In Vivo Maturation of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Neonatal and Adult Rat Hearts. Stem Cell Reports. 8(2):278-289.
(2017) Nathan J Palpant et al. Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells. Nat Protoc. 12(1):15-31.
(2016) Stephen C Kolwicz et al. AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. Mol Ther.; 24(2):240-250.
(2015) Sarah Fernandes et al. Comparison of Human Embryonic Stem Cell-Derived Cardiomyocytes, Cardiovascular Progenitors, and Bone Marrow Mononuclear Cells for Cardiac Repair. Stem Cell Reports. 5(5):753-762.
(2015) Shin Kadota et al. Ribonucleotide reductase-mediated increase in dATP improves cardiac performance via myosin activation in a large animal model of heart failure. Eur J Heart Fail. 17(8):772-81.
(2015) Kaytlyn Gerbin et al. Enhanced Electrical Integration of Engineered Human Myocardium via Intramyocardial versus Epicardial Delivery in Infarcted Rat Hearts. PLoS One. 10;10(7):e0131446.
(2014) James J H Chong et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature. 510(7504):273-7.
(2014) Scott D Lundy et al. Cell-based delivery of dATP via gap junctions enhances cardiac contractility. J Mol Cell Cardiol.;72:350-9.
(2012) Yuji Shiba et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature. 489(7415):322-5.
(2010) Sharon Paige et al. Endogenous Wnt/beta-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLos One. 15:5(6):e11134.
(2010) Sarah Fernandes et al. Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats. J Mol Cell Cardiol. 49(6):941-9.
(2007) Michael A Laflamme et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 25(9):1015-24.